Abstract:In order to explore possible biomarkers for predicting clinical outcomes and development of targeted therapies in T-cell malignancies (TCM, including T-cell lymphoma (TCL) and T-cell acute lymphoblastic leukemia (T-ALL)), the mechanisms and prognosis of abnormal expression and mutation of A20 (Also known as tumor necrosis factor-alpha-inducing protein 3, TNFAIP3) were analyzed from qRT-PCR data of T-ALL patients (n = 36) in our center and publicly available data. We found that low expression of A20 was associated with poor overall survival (OS) in TCM. Based on the results from PCR and Sanger-seq of TCL (n = 41) and T-ALL (n = 49), as well as exome-seq data of TCL (n = 79) and T-ALL (n = 54) in our center, we found that A20 mutation predicted favorable OS in TCL and poor OS in T-ALL. Notably, overexpression of A20 (A20-OV) promoted apoptosis and inhibited the proliferation of T-ALL cell lines Jurkat and KOPTK1, and TCL cell lines SUP-T1 and HUT78, especially treated with proteasome inhibitor MG132. In comparison with SUP-T1-B-NDG mice, the tumor volume and weight of the A20-OV SUP-T1-B-NDG mice decreased, and the survival time was prolonged. Regarding mechanisms, hypermethylation and histone deacetylation were found in the promoter DNA of A20. ChIP-seq data of the GSE25000 and knockdown of TAL1 in Jurkat and KOPTK1 cells or primary T-ALL cells indicated that TAL1 was a transcription factor for A20 in T-ALL. The expression of TRAF3 increased in A20-OV groups of malignant T cell lines by transcriptome sequencing and qRT-PCR, and decreased after knockdown of A20. In conclusion, A20 mutation and low expression were significantly associated with OS, and A20 might play an anti-tumor effect by regulating the expression of TRAF3, suggesting that A20 might be served as a candidate biomarker for prognostic stratification and targeted therapy for TCM. In order to explore possible biomarkers for predicting clinical outcomes and development of targeted therapies in T-cell malignancies (TCM, including T-cell lymphoma (TCL) and T-cell acute lymphoblastic leukemia (T-ALL)), the mechanisms and prognosis of abnormal expression and mutation of A20 (Also known as tumor necrosis factor-alpha-inducing protein 3, TNFAIP3) were analyzed from qRT-PCR data of T-ALL patients (n = 36) in our center and publicly available data. We found that low expression of A20 was associated with poor overall survival (OS) in TCM. Based on the results from PCR and Sanger-seq of TCL (n = 41) and T-ALL (n = 49), as well as exome-seq data of TCL (n = 79) and T-ALL (n = 54) in our center, we found that A20 mutation predicted favorable OS in TCL and poor OS in T-ALL. Notably, overexpression of A20 (A20-OV) promoted apoptosis and inhibited the proliferation of T-ALL cell lines Jurkat and KOPTK1, and TCL cell lines SUP-T1 and HUT78, especially treated with proteasome inhibitor MG132. In comparison with SUP-T1-B-NDG mice, the tumor volume and weight of the A20-OV SUP-T1-B-NDG mice decreased, and the survival time was prolonged. Regarding mechanisms, hypermethylation and histone deacetylation were found in the promoter DNA of A20. ChIP-seq data of the GSE25000 and knockdown of TAL1 in Jurkat and KOPTK1 cells or primary T-ALL cells indicated that TAL1 was a transcription factor for A20 in T-ALL. The expression of TRAF3 increased in A20-OV groups of malignant T cell lines by transcriptome sequencing and qRT-PCR, and decreased after knockdown of A20. In conclusion, A20 mutation and low expression were significantly associated with OS, and A20 might play an anti-tumor effect by regulating the expression of TRAF3, suggesting that A20 might be served as a candidate biomarker for prognostic stratification and targeted therapy for TCM.

A20 Suppresses Hepatocellular Carcinoma Proliferation and Metastasis Through Inhibition of Twist1 Expression

LncRNA AY promotes hepatocellular carcinoma metastasis by stimulating ITGAV transcription.

A20 inhibits the motility of HCC cells induced by TNF-α.

The Disassociation of the A20/HSP90 Complex via Downregulation of HSP90 Restores the Effect of A20 Enhancing the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeted Agents

Expression of A20 gene in hepatocellular carcinoma patients and its prognostic significance

A20 Enhances the Radiosensitivity of Hepatocellular Carcinoma Cells to 60Co-Γ Ionizing Radiation

A20 Interacts with Mtorc2 to Inhibit the Mtorc2/akt/rac1 Signaling Axis in Hepatocellular Carcinoma Cells.

Expression of Negative Immunoregulatory Gene A20 in Human Hepatocellular Carcinoma and Construction of Its Eukaryotic Expression Vector

Targeting A20 Enhances TRAIL-induced Apoptosis in Hepatocellular Carcinoma Cells

A20 Attenuates Liver Fibrosis in NAFLD and Inhibits Inflammation Responses

Inhibition of A20 Expression in Tumor Microenvironment Exerts Anti-Tumor Effect Through Inducing Myeloid-Derived Suppressor Cells Apoptosis

Altered Expression of A20 Gene in Peripheral Blood Mononuclear Cells is Associated with the Progression of Chronic Hepatitis B Virus Infection

ASF1B Serves As a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma

TCF12 promotes the tumorigenesis and metastasis of hepatocellular carcinoma via upregulation of CXCR4 expression.

Increased Cdc20 Expression Is Associated With Development And Progression Of Hepatocellular Carcinoma

The dual roles of A20 in cancer

A20 Promotes Melanoma Progression Via the Activation of Akt Pathway

Up-regulated A20 Promotes Proliferation, Regulates Cell Cycle Progression and Induces Chemotherapy Resistance of Acute Lymphoblastic Leukemia Cells.

Abstract 3093: Overexpression of Transcriptional Coactivator AIB1 Promotes Hepatocellular Carcinoma Progression by Enhancing Cell Proliferation and Invasiveness

Role of A20 in interferon-α-mediated functional restoration of myeloid dendritic cells in patients with chronic hepatitis C

3048 – MECHANISMS AND PROGNOSIS OF A20 MUTATION AND ABNORMAL EXPRESSION IN T-CELL MALIGNANCIES